Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 2/2017

01-06-2017 | Endoscopy (P Siersema, Section Editor)

Quality Indicators in Endoscopic Ablation for Barrett’s Esophagus

Authors: Samuel Han, MD, Sachin Wani, MD

Published in: Current Treatment Options in Gastroenterology | Issue 2/2017

Login to get access

Opinion Statement

Barrett’s esophagus (BE) is a well-established premalignant condition for esophageal adenocarcinoma (EAC); a cancer that is associated with a poor 5-year survival rate. Several strategies have been explored in the context of reducing the burden of EAC. Endoscopic eradication therapy (EET) is considered the standard of care for the management of patients with BE with dysplasia and early neoplasia; a practice that has been endorsed by all gastroenterology societal guidelines. The effectiveness of EET has been demonstrated in multiple studies and contemporary management includes a combination of endoscopic mucosal resection (EMR) of all visible lesions followed by eradication of the remaining BE using ablative techniques of which radiofrequency ablation (RFA) has the best evidence supporting effectiveness and safety. These techniques are being used increasingly at academic tertiary care centers and community practices. In this era of value-based health care, there is increased focus on the establishment, documentation, and reporting of quality indicators; indicators that are important to physicians, patients, and payers. The purpose of this review is to highlight the current status of quality indicators in EET for the management of patients with BE-related neoplasia and discuss the future steps required to ensure that these quality indicators are uniformly incorporated into practice.
Literature
1.
Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRefPubMed
2.
American Gastroenterological Association, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91.CrossRef
3.
Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–58.CrossRefPubMed
4.
Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–86, 1186 e1.CrossRefPubMed
5.
Wani S. Population-based estimates of cancer and mortality in Barrett’s esophagus: implications for the future. Clin Gastroenterol Hepatol. 2011;9:723–4.CrossRefPubMed
6.
Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–8.CrossRefPubMed
7.
Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–83.CrossRefPubMed
8.
Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57.CrossRefPubMedPubMedCentral
9.
ASGE Standards of Practice Committee., Evans JA, Early JA, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012; 76(6): 1087–94.
10.
•• Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–17. This randomized multicenter trial compares radiofrequency ablation to endoscopic surveillance alone in low grade dysplasia in Barrett’s demonstrating the superiority of the former in eradicating Barrett’sCrossRefPubMed
11.
•• Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277. This landmark trial demonstrated the efficacy of radiofrequency ablation in treating and eradicating dysplastic Barrett’s Esophagus.CrossRefPubMed
12.
• Overholt BF, Lightdale CJ, Wang KA, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–98. This multicentered randomized trial compares photodynamic therapy to omeprazole alone, demonstrating the effectiveness of photodynamic therapy in treating high-grade dysplasia.CrossRefPubMed
13.
Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–6.CrossRefPubMed
14.
Manner H, Pech O, Heldmann Y, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol. 2013;11:630–5.CrossRefPubMed
15.
Wani S, Rubenstein JH, Vieth M, et al. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the clinical practice updates Committee of the American Gastroenterological Association. Gastroenterology. 2016;151(5):822–35.CrossRefPubMed
16.
Qumseya BJ, Wani S, Desai M, et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1086–95.CrossRefPubMed
17.
Council of the Institute of Medicine. America’s health in transition: protecting and improving quality. Washington, DC: National Academy Press; 1994.
18.
19.
Petersen BT. Quality assurance for endoscopists. Best Pract Res Clin Gastroenterol. 2011;25:349–60.CrossRefPubMed
20.
Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on health care quality. JAMA. 1998;280:1000–5.CrossRefPubMed
21.
Rizk MK, Sawhney MS, Cohen J, et al. Quality indicators common to all GI endoscopic procedures. Gastrointest Endosc. 2015;81(1):3–16.CrossRefPubMed
22.
•• Sharma P, Katzka DA, Gupta N. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association symposium. Gastroenterology. 2015;149:1599–606. This expert panel position paper represents the consensus statement produced by the American Gastroenterological Association in regards to quality indicators for the management of Barrett’s Esophagus and Esophageal Adenocarcinoma.CrossRefPubMedPubMedCentral
23.
•• Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (treatment with resection and endoscopic ablation techniques for Barrett’s esophagus) consortium. Gastrointest Endosc. 2017; In press. This study presents the findings by the TREAT-BE consortium relating to quality indicators in endoscopic techniques for the management of Barrett’s Esophagus.
24.
Fitch K, Aguilar MD, Burnand B, et al. The RAND/UCLA appropriateness method user’s manual. Santa Monica: RAND; 2001.
25.
McKenna BJ, Appelman HD. Dysplasia of the gut: the diagnosis is harder than it seems. J Clin Gastroenterol. 2002;34:111–6.CrossRefPubMed
26.
Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.CrossRefPubMed
27.
Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700–6.CrossRefPubMed
28.
Sangle NA, Taylor SL, Emond MJ, et al. Overdiagnosis of high-grade dysplasia in Barrett’s esophagus: a multicenter, international study. Mod Pathol. 2015;28:758–65.CrossRefPubMed
29.
30.
Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett’s esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379–88.CrossRefPubMed
31.
Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–780.CrossRefPubMed
32.
Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed
33.
Schölvinck DW, van der Meulen K, Bergman JJ, Weusten BL. Detection of lesions in dysplastic Barrett’s esophagus by community and expert endoscopists. Endoscopy. 2016.
34.
Wani S, Sharma P. Challenges with endoscopic therapy for Barrett’s esophagus. Gastroenterol Clin N Am. 2015;44:355–72.CrossRef
35.
Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.CrossRefPubMed
36.
Anonymous. Paris workshop on columnar metaplasia in the esophagus and the Esophagogastric junction, Paris, France, December 11-12 2004. Endoscopy. 2005;37:879–920.CrossRef
37.
Wolfsen HC, Crook JE, Krishna M, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s esophagus. Gastroenterology. 2008;135:24–31.CrossRefPubMed
38.
Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37:929–36.CrossRefPubMed
39.
Curvers W, Baak L, Kiesslich R, et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett’s esophagus. Gastroenterology. 2008;134:670–9.CrossRefPubMed
40.
Sami SS, Subramanian V, Butt WM, et al. High definition versus standard definition white light endoscopy for detecting dysplasia in patients with Barrett’s esophagus. Dis Esophagus. 2015;28:742–9.CrossRefPubMed
41.
Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett’s esophagus. Gastrointest Endosc. 2005;62:16–23.CrossRefPubMed
42.
Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest Endosc. 2008;67:604–9.CrossRefPubMed
43.
Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol. 2010;105:1276–83.CrossRefPubMed
44.
Chennat J, Konda VJ, Ross AS, et al. Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. Am J Gastroenterol. 2009;104:2684–92.CrossRefPubMed
45.
Wani S, Abrams J, Edmundowicz SA, et al. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett’s esophagus patients with visible and flat neoplasia: a multicenter cohort study. Digestive Diseases & Sciences. 2013;58:1703–9.CrossRef
46.
Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett’s dysplasia. Clinical Gastroenterology & Hepatology. 2010;8:783–8.CrossRef
47.
Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007;66:660–6. quiz 767, 769CrossRefPubMed
48.
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–55.CrossRefPubMed
49.
van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011;60:765–73.CrossRefPubMed
50.
Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US multicenter consortium. Gastroenterology. 2013;145:79–86.CrossRefPubMedPubMedCentral
51.
Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370–9.CrossRefPubMed
52.
Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8:23–9.CrossRefPubMed
53.
Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781–9.CrossRefPubMed
54.
Vaccaro BJ, Gonzalez S, Poneros JM, et al. Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci. 2011;56:1996–2000.CrossRefPubMedPubMedCentral
55.
Haidry RJ, Banks M, Gupta A, et al. Recurrence after successful radiofrequency ablation for Barrett’s related neoplasia is more likely in males: data from the United Kingdom patient registry. Gut. 2014;63:A113–4.
56.
Cotton CC, Wolf WA, Pasricha S, et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc. 2015;81:1362–9.CrossRefPubMedPubMedCentral
57.
Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108:187–95.CrossRefPubMed
58.
Prasad GA, Dunagan KT, Tian J, et al. Recurrence of intestinal metaplasia following radiofrequency ablation: rates and predictors. Gastrointest Endosc. 2011;73:AB145–6.
59.
Krishnan K, Pandolfino JE, Kahrilas PJ, et al. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143:576–81.CrossRefPubMedPubMedCentral
60.
Yasuda K, Choi SE, Nishioka NS, et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett’s esophagus. Digestive Diseases & Sciences. 2014;59:1560–6.CrossRef
61.
Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci. 2012;57:2625–32.CrossRefPubMed
62.
Leiman DA, Metz DV, Ginsberg GG, et al. A novel electronic medical record-based workflow to measure and report colonoscopy quality measures. Clin Gastroenterol Hepatol. 2016;14(3):333–7.CrossRefPubMed
63.
Mehta SJ, Ahmad NA. Aligning quality with the academic mission: a quality improvement and delivery science Program in gastroenterology. Gastroenterology. 2016;150(3):543–6.CrossRefPubMed
Metadata
Title
Quality Indicators in Endoscopic Ablation for Barrett’s Esophagus
Authors
Samuel Han, MD
Sachin Wani, MD
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 2/2017
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-017-0136-0

Other articles of this Issue 2/2017

Current Treatment Options in Gastroenterology 2/2017 Go to the issue

Liver (J Bajaj, Section Editor)

Role of Zinc in the Development/Progression of Alcoholic Liver Disease

Liver (J Bajaj, Section Editor)

Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices

Endoscopy (P Siersema, Section Editor)

Endoscopic Management of Benign Esophageal Ruptures and Leaks

Endoscopy (P Siersema, Section Editor)

Endoscopy in Patients on Antiplatelet Agents and Anticoagulants

Liver (J Bajaj, Section Editor)

Management of Cirrhotic Patients After Successful HCV Eradication

Liver (J Bajaj, Section Editor)

Liver Transplantation: the Role of Metabolic Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits